November 26, 2015
Recommended Topic Related To:


"Managing HIV could get a lot easier with a new delivery system for anti-AIDS drugs.

Instead of daily pills, the treatment could lead to drugs that can be administered just once or twice per year.

The new delivery system, designed "...


Side Effects


The following adverse reactions are discussed in other sections of the labeling:

Clinical Trials Experience In Adult Subjects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety profile of EPIVIR in adults is primarily based on 3,568 HIV-1-infected subjects in 7 clinical trials.

The most common adverse reactions are headache, nausea, malaise, fatigue, nasal signs and symptoms, diarrhea, and cough.

Selected clinical adverse reactions in greater than or equal to 5% of subjects during therapy with EPIVIR 150 mg twice daily plus RETROVIR® 200 mg 3 times daily for up to 24 weeks are listed in Table 3.

Table 3: Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in Four Controlled Clinical Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002)

Adverse Reaction EPIVIR 150 mg Twice Daily plus RETROVIR
(n = 251)
(n = 230)
Body as a Whole
  Headache 35% 27%
  Malaise & fatigue 27% 23%
  Fever or chills 10% 12%
  Nausea 33% 29%
  Diarrhea 18% 22%
  Nausea & vomiting 13% 12%
  Anorexia and/or decreased appetite  10% 7%
  Abdominal pain 9% 11%
  Abdominal cramps 6% 3%
  Dyspepsia 5% 5%
Nervous System
  Neuropathy 12% 10%
  Insomnia & other sleep disorders 11% 7%
  Dizziness 10% 4%
  Depressive disorders 9% 4%
  Nasal signs & symptoms 20% 11%
  Cough 18% 13%
  Skin rashes 9% 6%
  Musculoskeletal pain 12% 10%
  Myalgia 8% 6%
  Arthralgia 5% 5%
a Either zidovudine monotherapy or zidovudine in combination with zalcitabine.

Pancreatitis: Pancreatitis was observed in 9 out of 2,613 adult subjects (0.3%) who received EPIVIR in controlled clinical trials EPV20001, NUCA3001, NUCB3001, NUCA3002, NUCB3002, and NUCB3007 [see WARNINGS AND PRECAUTIONS].

EPIVIR 300 mg Once Daily: The types and frequencies of clinical adverse reactions reported in subjects receiving EPIVIR 300 mg once daily or EPIVIR 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) for 48 weeks were similar.

Selected laboratory abnormalities observed during therapy are summarized in Table 4.

Table 4: Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Adults in Four 24-Week Surrogate Endpoint Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002) and a Clinical Endpoint Trial (NUCB3007)

Test (Threshold Level) 24-Week Surrogate Endpoint Trialsa Clinical Endpoint Triala
EPIVIR plus RETROVIR RETROVIRb EPIVIR plus Current Therapyc Placebo plus Current Therapyc
Absolute neutrophil count ( < 750/mm³) 7.2% 5.4% 15% 13%
Hemoglobin ( < 8.0 g/dL) 2.9% 1.8% 2.2% 3.4%
Platelets ( < 50,000/mm³) 0.4% 1.3% 2.8% 3.8%
ALT ( > 5.0 x ULN) 3.7% 3.6% 3.8% 1.9%
AST ( > 5.0 x ULN) 1.7% 1.8% 4.0% 2.1%
Bilirubin ( > 2.5 x ULN) 0.8% 0.4% ND ND
Amylase ( > 2.0 x ULN) 4.2% 1.5% 2.2% 1.1%
a The median duration on study was 12 months.
b Either zidovudine monotherapy or zidovudine in combination with zalcitabine.
c Current therapy was either zidovudine, zidovudine plus didanosine, or zidovudine plus zalcitabine.
ULN = Upper limit of normal.
ND = Not done.

The frequencies of selected laboratory abnormalities reported in subjects receiving EPIVIR 300 mg once daily or EPIVIR 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) were similar.

Clinical Trials Experience In Pediatric Subjects

EPIVIR oral solution has been studied in 638 pediatric subjects aged 3 months to 18 years in 3 clinical trials.

Selected clinical adverse reactions and physical findings with a greater than or equal to 5% frequency during therapy with EPIVIR 4 mg per kg twice daily plus RETROVIR 160 mg per m² 3 times daily in therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 5.

Table 5: Selected Clinical Adverse Reactions and Physical Findings (Greater than or Equal to 5% Frequency) in Pediatric Subjects in Trial ACTG300

Adverse Reaction EPIVIR plus RETROVIR
(n = 236)
(n = 235)
Body as a Whole
  Fever 25% 32%
  Hepatomegaly 11% 11%
  Nausea & vomiting 8% 7%
  Diarrhea 8% 6%
  Stomatitis 6% 12%
  Splenomegaly 5% 8%
  Cough 15% 18%
  Abnormal breath sounds/wheezing 7% 9%
Ear, Nose, and Throat
  Signs or symptoms of earsa 7% 6%
  Nasal discharge or congestion 8% 11%
  Skin rashes 12% 14%
  Lymphadenopathy 9% 11%
a Includes pain, discharge, erythema, or swelling of an ear.


Pancreatitis, which has been fatal in some cases, has been observed in antiretroviral nucleoside-experienced pediatric subjects receiving EPIVIR alone or in combination with other antiretroviral agents. In an open-label dose-escalation trial (NUCA2002), 14 subjects (14%) developed pancreatitis while receiving monotherapy with EPIVIR. Three of these subjects died of complications of pancreatitis. In a second open-label trial (NUCA2005), 12 subjects (18%) developed pancreatitis. In Trial ACTG300, pancreatitis was not observed in 236 subjects randomized to EPIVIR plus RETROVIR. Pancreatitis was observed in 1 subject in this trial who received open-label EPIVIR in combination with RETROVIR and ritonavir following discontinuation of didanosine monotherapy [see WARNINGS AND PRECAUTIONS].

Paresthesias and Peripheral Neuropathies

Paresthesias and peripheral neuropathies were reported in 15 subjects (15%) in Trial NUCA2002, 6 subjects (9%) in Trial NUCA2005, and 2 subjects (less than 1%) in Trial ACTG300.

Selected laboratory abnormalities experienced by therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 6.

Table 6: Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Pediatric Subjects in Trial ACTG300

(Threshold Level) RETROVIR Didanosine
Absolute neutrophil count ( < 400/mm ) 8% 3%
Hemoglobin ( < 7.0 g/dL) 4% 2%
Platelets ( < 50,000/mm³) 1% 3%
ALT ( > 10 x ULN) 1% 3%
AST ( > 10 x ULN) 2% 4%
Lipase ( > 2.5 x ULN) 3% 3%
Total Amylase ( > 2.5 x ULN) 3% 3%
ULN = Upper limit of normal.

Pediatric Subjects Once-daily versus Twice-daily Dosing (COL105677)

The safety of once-daily compared with twice-daily dosing of EPIVIR was assessed in the ARROW trial. Primary safety assessment in the ARROW trial was based on Grade 3 and Grade 4 adverse events. The frequency of Grade 3 and 4 adverse events was similar among subjects randomized to once-daily dosing compared with subjects randomized to twice-daily dosing. One event of Grade 4 hepatitis in the once-daily cohort was considered as uncertain causality by the investigator and all other Grade 3 or 4 adverse events were considered not related by the investigator.


Limited short-term safety information is available from 2 small, uncontrolled trials in South Africa in neonates receiving lamivudine with or without zidovudine for the first week of life following maternal treatment starting at Week 38 or 36 of gestation [see CLINICAL PHARMACOLOGY]. Selected adverse reactions reported in these neonates included increased liver function tests, anemia, diarrhea, electrolyte disturbances, hypoglycemia, jaundice and hepatomegaly, rash, respiratory infections, and sepsis; 3 neonates died (1 from gastroenteritis with acidosis and convulsions, 1 from traumatic injury, and 1 from unknown causes). Two other nonfatal gastroenteritis or diarrhea cases were reported, including 1 with convulsions; 1 infant had transient renal insufficiency associated with dehydration. The absence of control groups limits assessments of causality, but it should be assumed that perinatally exposed infants may be at risk for adverse reactions comparable to those reported in pediatric and adult HIV-1-infected patients treated with lamivudine-containing combination regimens. Long-term effects of in utero and infant lamivudine exposure are not known.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of EPIVIR.

Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine.

Body as a Whole

Redistribution/accumulation of body fat [see WARNINGS AND PRECAUTIONS].

Endocrine and Metabolic




Hemic and Lymphatic

Anemia (including pure red cell aplasia and severe anemias progressing on therapy).

Hepatic and Pancreatic

Lactic acidosis and hepatic steatosis [see WARNINGS AND PRECAUTIONS], posttreatment exacerbations of hepatitis B [see WARNINGS AND PRECAUTIONS].


Anaphylaxis, urticaria.


Muscle weakness, CPK elevation, rhabdomyolysis.


Alopecia, pruritus.

Read the Epivir (lamivudine) Side Effects Center for a complete guide to possible side effects


Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim) [see Pharmacokinetics]. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.

Read the Epivir Drug Interactions Center for a complete guide to possible interactions

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/23/2015

Side Effects

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.